Loading...
Market
What will be the market share of FluMist nasal spray in the U.S. flu vaccine market by end of 2024?
2
Resolution / Starting Odds
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Industry reports or AstraZeneca's financial disclosures
Story
FDA Approves AstraZeneca's FluMist Nasal Spray, First Self-Administered Flu Vaccine
Sep 20, 2024, 08:06 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This marks the first time a flu vaccine can be administered at home without the need for a healthcare provider, making it the first of its kind. The vaccine, which is licensed for individuals aged 2 to 49, aims to increase accessibility and reduce barriers to flu vaccination. It will be available through third-party pharmacies, where users will complete a screening and eligibility assessment. The approval aligns with the FDA's broader efforts to expand consumer access to medications and reduce healthcare costs.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%
Very Satisfied • 25%
Satisfied • 25%
Neutral • 25%
Dissatisfied • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%